Extended Data Fig. 5: Cohort flow diagrams for the primary comparisons.
From: Varicella-zoster virus reactivation and the risk of dementia
Comparison of dementia outcomes for cohorts that experienced multiple vs a single HZ episode (a), that were exposed to ZVL vs PPSV23 (b) and that were exposed to RZV (2+ doses) vs PPSV23 (c). Multiple and single HZ, individuals experiencing at least 2 (multiple) and 1 (single) episodes of herpes zoster (HZ); MCI, mild cognitive impairment; OW, overlap weighting; PPSV23, recipients of at least 1 dose of a 23-valent pneumococcal polysaccharide vaccine; RZV (2+ doses), recipients of at least 2 doses of the recombinant zoster vaccine (Shingrix, GSK); ZVL, recipients of at least 1 dose of the live-attenuated zoster vaccine (Zostavax, Merck).
